Intel stock extends gains after report of possible U.S. government stake
Nimrata Hunt, Executive Vice President at IDEXX Laboratories (NASDAQ:IDXX), sold 1,200 shares of common stock on August 11 at $656.5335, totaling $787840. The transaction comes as IDEXX shares trade near their 52-week high of $688.12, with the stock showing remarkable strength, up nearly 58% year-to-date.
According to a Form 4 filing with the Securities and Exchange Commission, Hunt also exercised options to acquire a total of 1,226 shares of IDEXX common stock on August 12. These transactions involved the exercise of stock options at prices ranging from $178.26 to $544.08, resulting in a total value of $299344. With a market capitalization of $53.15 billion and a P/E ratio of 54.87, IDEXX currently trades above its InvestingPro Fair Value. The company maintains a "GREAT" financial health score, with 14 additional key insights available through InvestingPro’s comprehensive analysis.
In other recent news, IDEXX Laboratories reported a strong second quarter for 2025, exceeding both earnings and revenue expectations. The company achieved an earnings per share of $3.63, surpassing the projected $3.29, which marks a 17% increase from the previous year. Revenue reached $1.11 billion, exceeding the anticipated $1.06 billion. Jefferies responded to these robust results by raising its price target for IDEXX Laboratories from $625 to $785, while maintaining a Buy rating. The company experienced sales growth of 10.6% and EBITDA growth of 14% during the quarter. These recent developments indicate solid performance and positive sentiment from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.